ARCHER 1050: A RANDOMIZED, OPEN-LABEL, PHASE 3, EFFICACY AND SAFETY STUDY OF DACOMITINIB (PF 00299804) VERSUS GEFITINIB FOR THE FIRST LINE TREATMENT OF LOCALLY ADVANCED OR METASTATIC NON SMALL CELL LUNG CANCER IN SUBJECTS WITH EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) ACTIVATING MUTATION(S)

Trial Profile

ARCHER 1050: A RANDOMIZED, OPEN-LABEL, PHASE 3, EFFICACY AND SAFETY STUDY OF DACOMITINIB (PF 00299804) VERSUS GEFITINIB FOR THE FIRST LINE TREATMENT OF LOCALLY ADVANCED OR METASTATIC NON SMALL CELL LUNG CANCER IN SUBJECTS WITH EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) ACTIVATING MUTATION(S)

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 20 Dec 2017

At a glance

  • Drugs Dacomitinib (Primary) ; Gefitinib
  • Indications Non-small cell lung cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms ARCHER-1050
  • Sponsors SFJ Pharmaceuticals
  • Most Recent Events

    • 13 Dec 2017 Planned End Date changed from 1 Sep 2017 to 1 Mar 2019.
    • 18 Oct 2017 Results reporting the impact of dacomitinib and gefitinib treatment on core lung cancer symptoms presented at the 18th World Conference on Lung Cancer
    • 18 Oct 2017 Results assessing first-Line Dacomitinib versus gefitinib in patients with advanced non-small-cell lung cancer with Egfr mutation subgroups, presented at the 18th World Conference on Lung Cancer.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top